Time filter

Source Type

KALAMAZOO, MI, United States

Colca J.R.,Metabolic Solutions Development Co
Expert Opinion on Investigational Drugs | Year: 2013

Introduction: This perspective summarizes 42 drug projects in the general areas of endocrine and metabolic diseases that were reported discontinued during 2012. Areas covered: These programs include development projects against diabetes, metabolic complications (including kidney and liver disease), as well as projects that can be described as approaches to treatment of obesity/anorexia, lipids and various inflammatory diseases. Candidates were identified from a search by Informa Healthcare including data available on TreasureTrove as provided by EOID. Additional information was sought using Google, PubMed, HighWire and ClinicalTrials.gov. Expert opinion: The summary of discontinued projects in this area for 2012 provides little in the way of specific guidance especially since details of the fate of most projects are often lacking. Nonetheless, it seems clear that none of these projects has hit upon the key aspects of the pathophysiology of the disorders that they were intended to treat, and the most likely cause of failure is the lack of the ability to produce compelling evidence to support the respective business case in the sense of efficacy/potential therapeutic profile. © Informa UK, Ltd. Source

Colca J.R.,Metabolic Solutions Development Co
Expert Opinion on Investigational Drugs | Year: 2015

Introduction: Available drugs partially attenuate the hyperglycemia characteristic of diabetes. However, successful approaches to treat the root cause or to cure or prevent diabetes remain elusive. Drug discovery and development programs continue to focus on mechanisms that impact specific symptoms of diabetes. In 2014, programs were discontinued for a variety of reasons and these discontinued programs are discussed herein.Areas covered: A search of discontinued products in the metabolic area for 2014 identified mostly compounds that were being developed to treat diabetes (mostly type 2 diabetes). Candidates were identified through the use of PharmaProjects. The author also sought information using Google, PubMed, HighWire and ClinicalTrials.gov. The discontinued development programs that were identified were not numerous as in previous years and so they are presented here without segregation into categories.Expert opinion: In general, the specific reasons for the discontinuation of these programs have not been clearly disclosed. In some cases, business considerations are given, whereas in others, there are specific safety issues that emerged which were not expected from nonclinical experience. In the final analysis, it is clear that all of these programs have been discontinued because the evidence does not favor the type of efficacy and risk:benefit ratio that justifies additional expenditures. There remains a clear need for precise addressable mechanisms to affect the root causes of diabetes. © 2015 © Informa UK, Ltd. Source

Metabolic Solutions Development Co | Date: 2014-12-30

The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes.

Metabolic Solutions Development Co | Date: 2014-10-30

The present invention relates to novel salts of thiazolidinediones and other pharmaceutical agents that are useful for treating and/or preventing metabolic diseases (e.g., diabetes, or neurodegenerative diseases (e.g., Alzheimers Disease).

Metabolic Solutions Development Co | Date: 2014-09-05

The present invention provides novel methods for synthesizing PPAR sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases.

Discover hidden collaborations